Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 30, 2026

Stocks Rally as Nasdaq 100 Posts a New Record High on Tech Earnings

View original at nasdaq.com
Stocks Rally as Nasdaq 100 Posts a New Record High on Tech Earnings The S&P 500 Index ($SPX) (SPY) today is up +0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.20%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.17%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Unchanged interest rates are a reasonable place to be.

    60% confidence

  • Incoming information suggests the conflict is weighing on economic activity, surveys point to slowing growth, and consumers and businesses have become less confident about the future.

    60% confidence

  • The economic growth outlook is highly uncertain and will depend on how long the war in the Middle East will last, how strongly it affects energy and other commodity markets, as well as global supply chains.

    60% confidence

  • Powell will continue to serve as Fed Governor for a period of time to be determined after his chair term ends.

    60% confidence

  • Qualcomm is excited about its entry into data centers, where a leading hyperscaler custom silicon engagement is on track for initial shipments later this year.

    60% confidence

  • The upside risks to inflation and the downside risks to growth have intensified.

    60% confidence

Data points we hold from this source

Federal Reserve · fomc rate cut probability next meeting3 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Rally as Nasdaq 100 Posts a New Record High on Tech Earnings — Source | Via News | Via News